Six readers
| reader | found | score |
|---|---|---|
| genetics Open Targets | no genetic evidence; overall 0.06 from other evidence | 0.00 |
| cell type Human Protein Atlas | not detected in single-cell data | 0.00 |
| chemistry Open Targets | compounds already reach it: amifampridine, guanidine hydrochloride, amifampridine phosphate +3 | 1.00 |
| trials ClinicalTrials.gov | 6 Parkinson's trials, 1 stopped | 0.87 |
| literature PubMed | 1 Parkinson's papers of 26 | 0.91 |
| pathways Reactome | 1 pathway; mostly dopamine synapse | 1.00 |
No case: the score is under the bar. Receipt 4677
Sealed predictions
- KCNA10 in dopamine neurons, braak-0.02 (p 0.965) → +0.06 (p 0.888)receipt 4685
Swarm cases
receipt 4685: KCNA10 in dopamine neurons, braak
- power
- full sample -0.15 (p 0.543, n 18), 95% CI -0.58 to +0.34. the interval is wide: not enough donors to tell.
- confounder
- adjusted for sex: -0.07 (p 0.787, n 18). does not hold up.
- composition
- dopamine neurons share of nuclei vs axis +0.05 (p 0.854); controlling for it: -0.41 (p 0.091, n 18). could be the mix.
- skeptic
- leave-one-out range -0.27 to -0.03, sign flips 0; without severely affected donors -0.15 (p 0.543, n 18). fragile.
- cell type
- no other cell group does better.
- axis
- no measure beats "tracks Braak Lewy-body stage" for KCNA10 in dopamine neurons.
case closed: nothing better to follow up.
Receipts
loading the receipts